TY - JOUR
T1 - Time to revise COPD treatment algorithm
AU - Matsunaga, Kazuto
AU - Oishi, Keiji
AU - Miravitlles, Marc
AU - Anzueto, Antonio
N1 - Funding Information:
Kazuto Matsunaga has received consulting fees and lecture fees from Boehringer Ingelheim, Astellas, Astra-Zeneca, Sanofi, Meiji-Seika Pharma, Novartis, Kyorin Pharma, Chest, Torii pharma, and GlaxoSmithKline, outside the submitted work. Keiji Oishi reports speaker fees from Boehringer Ingelheim, Astra-Zeneca, Meiji-Seika Pharma, Novartis, Kyorin Pharma, outside the submitted work. Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, pH Pharma, Novartis and Grifols and research grants from GlaxoSmithKline and Grifols, outside the submitted work. Antonio Anzueto has received consulting fees, lecture fees, and travel support from AstraZeneca, Boehringer Ingelheim, Sunovion, GlaxoSmithKline, and Novartis, and grant support from GlaxoSmithKline, outside the submitted work. The authors report no other conflicts of interest in this work.
PY - 2019
Y1 - 2019
N2 - In 2017, a new two-step algorithm for the treatment of COPD was proposed. This algorithm was based on the severity of symptoms and phenotypes or treatable traits, and patient-specialised assessment targeting eosinophilic inflammation, chronic bronchitis, and frequent infections is recommended after exacerbation occurs despite maximal bronchodilation therapy. However, recent studies have revealed the clinical characteristics of patients who should have second controllers added, such as ICS. We again realized that treatable traits should be assessed and intervened for as early as possible. Moreover, the treatment algorithm is necessary to be adapted to the situation of clinical practice, taking into account the characteristics of the patients. The time to revise COPD treatment algorithm has come and we propose a new 3-step parallel approach for initial COPD treatment. After the diagnosis of COPD, the first assessment is to divide into two categories based on the usual clinical characteristics for patients with COPD and the specific clinical characteristics for each patient with concomitant disease. In the former, the assessment should be based on the level of dyspnea and the frequency of exacerbations. After the assessment, mono- or dual bronchodilator should be selected. In the latter, the assessment should be based on asthma characteristics, chronic bronchitis, and chronic heart failure. After the assessment, patients with asthmatic characteristics may consider treatment with ICS, while patients with chronic bronchitis may consider treatment with roflumilast and/or macrolide, while patients with chronic heart failure may consider treatment with selective Β1-blocker. The 3-step parallel approach is completed by adding an additional therapy for patients with concomitant disease to essential therapy for patients with COPD. In addition, it is important to review the response around 4 weeks after the initial therapy. This COPD management proposal might be considered as an approach based on patients’ clinical characteristics and on personalized therapy.
AB - In 2017, a new two-step algorithm for the treatment of COPD was proposed. This algorithm was based on the severity of symptoms and phenotypes or treatable traits, and patient-specialised assessment targeting eosinophilic inflammation, chronic bronchitis, and frequent infections is recommended after exacerbation occurs despite maximal bronchodilation therapy. However, recent studies have revealed the clinical characteristics of patients who should have second controllers added, such as ICS. We again realized that treatable traits should be assessed and intervened for as early as possible. Moreover, the treatment algorithm is necessary to be adapted to the situation of clinical practice, taking into account the characteristics of the patients. The time to revise COPD treatment algorithm has come and we propose a new 3-step parallel approach for initial COPD treatment. After the diagnosis of COPD, the first assessment is to divide into two categories based on the usual clinical characteristics for patients with COPD and the specific clinical characteristics for each patient with concomitant disease. In the former, the assessment should be based on the level of dyspnea and the frequency of exacerbations. After the assessment, mono- or dual bronchodilator should be selected. In the latter, the assessment should be based on asthma characteristics, chronic bronchitis, and chronic heart failure. After the assessment, patients with asthmatic characteristics may consider treatment with ICS, while patients with chronic bronchitis may consider treatment with roflumilast and/or macrolide, while patients with chronic heart failure may consider treatment with selective Β1-blocker. The 3-step parallel approach is completed by adding an additional therapy for patients with concomitant disease to essential therapy for patients with COPD. In addition, it is important to review the response around 4 weeks after the initial therapy. This COPD management proposal might be considered as an approach based on patients’ clinical characteristics and on personalized therapy.
KW - ICS
KW - Parallel approach
KW - Personalized therapy
KW - Treatable traits
UR - http://www.scopus.com/inward/record.url?scp=85073607139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073607139&partnerID=8YFLogxK
U2 - 10.2147/COPD.S219051
DO - 10.2147/COPD.S219051
M3 - Article
C2 - 31631994
AN - SCOPUS:85073607139
VL - 14
SP - 2229
EP - 2234
JO - International Journal of COPD
JF - International Journal of COPD
SN - 1176-9106
ER -